AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04785560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Initial shunt setting post-operatively of the Certas Plus shunt valve.
Description: The setting/resistance of the Certas Plus Shunt valve implanted is set according to randomisation and is not changed until the first post-operative MRI is performed 36-48 hours after surgery.
Study NCT04822935 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertebral Body Tethering
Description: VBT surgery is a surgery performed by thoracotomy in adolescent idiopathic scoliosis patients.
Study NCT05850104 — intervention group
Intervention type: OTHER
Intervention: the effects of classical Chopart prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation.
Description: the effects of classical Chopart prosthesis and silicone prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation.
Study NCT05850104 — intervention group
Intervention type: OTHER
Intervention: the effects of silicone prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation.
Description: the effects of silicone prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation.
Study NCT05638516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vira mobile app intervention
Description: The Vira app is installed on the participant's phone. The app passively collects data from phone sensors (i.e., measures of physical activity, sleep patterns, mobility, and language patterns reflecting mood states and cognition) that are indicative of risk-relevant behavioral patterns and psychological states. It also so prompts users to answer a daily check in question. Mobile sensing data are processed to provide an automated assessment of the user's functioning. Users will be asked to use Vira for 12 weeks.
Study NCT05638516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vira mobile app intervention + coaching
Description: The Vira app can also be supported by a health coach. The health coach interacts with the user (via an instant messaging platform) and who also schedules just-in-time reminders (i.e., nudges) to arrive in the user's phone at scheduled times to support their behavior change plan. The Vira Health Coach Platform therefore integrates mobile sensing, self-report assessment, and just-in-time nudges and notifications into the coach's workflow.
Study NCT03907020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Barley
Description: Assessing the metabolic availability of lysine in barley.
Study NCT05382598 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renal replacement therapy
Description: Renal replacement therapy (RRT) will be initiated in the early group for patients who have stage 2 AKI according to KDIGO classification. The late group will have RRT when they develop any of the absolute indications for RRT
Study NCT05411874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 5mg po biw for 24 weeks
Study NCT05012215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paravertebral
Description: Ultrasound-guided paravertebral block
Study NCT05012215 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal block
Description: Caudal block
Study NCT04781647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABI-H0731
Description: Participants will receive ABI-H0731 300 mg tablets orally once daily
Study NCT04781647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H0731
Description: Participants will receive ABI-H0731 300 mg tablets orally once daily
Study NCT04781647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ETV
Description: Participants will receive ETV 0.5 mg tablets orally once daily
Study NCT05411874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD-DXM
Description: 40mg po qd for 4days
Study NCT05411874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HD-DXM
Description: 40mg po qd for 4days
Study NCT06442449 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sIPV
Description: vaccination with sIPV
Study NCT06442449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV
Description: vaccination with sIPV
Study NCT06442449 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMR
Description: vaccination with MMR
Study NCT06442449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR
Description: vaccination with MMR
Study NCT06442449 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HepA-I
Description: vaccination with HepA-I
Study NCT06442449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HepA-I
Description: vaccination with HepA-I
Study NCT05462275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubation using 3-cuffed double lumen endotracheal tube
Description: After patient's position, 3-cuffed double lumen endotracheal tube is intubated without fiberoptic bronchoscopy guidance
Study NCT04937907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate 100 milligram (mg) Tab
Description: Patients administered HCQ by oral at a dose of 6.5mg per kilogram twice a day at least 6 months.
Study NCT04937907 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Benazepril hydrochloride 10 milligram (mg) Tab
Description: Patients administered Benazepril by oral at a dose of 5mg or 10mg once a day at least 6 months.
Study NCT04937907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril hydrochloride 10 milligram (mg) Tab
Description: Patients administered Benazepril by oral at a dose of 5mg or 10mg once a day at least 6 months.
Study NCT03972020 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Intervention
Description: The MBI used in this study is called body-affective mindfulness (BAM); BAM is based on:~(1) awareness practices such as body scan, breath meditation, walking meditation and yoga exercises; (2) mindfulness in relationship practices such as loving kindness, enriching listening to nature and persons and self-compassion; (3) sensorimotor psychotherapy Sensorimotor psychotherapy emphasizes the use of somatic resources to attain and sustain a mindful disposition and integrates the concept of a stress response with the concept of a window of tolerance in order to maximize the clinical utility of the intervention and tailor it to breast cancer patients.
Study NCT03972020 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Cognitive behavior therapies will include cognitive restructuring, relaxation, skills training, and visual imagery, among other modalities.
Study NCT05636072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WISER
Description: Participants will engage in one or more positive psychology well-being tool(s).
Study NCT05993091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mirror therapy (MT)
Description: Each participant will practice two different MT protocols: UMT and BMT. During UMT, the affected hand is static, whereas during BMT, the affected hand moves in an attempt to duplicate the unaffected hand as best as possible. The MT activities include gross motor movements (i.e., shoulder flexion, elbow flexion/extension, forearm pronation/supination, and wrist flexion/extension and circumduction), fine motor movements (i.e., opposition, grasp, and release), and object manipulation (i.e., reaching out to grasp a cup, flipping coins).
Study NCT05993091 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: augmented reality (AR)
Description: The training program with different levels of difficulty provides goal-directed exercises designed to be adjustable in order to match the patient's ability to minimize compensatory movements. The goal-directed exercise includes balance training (i.e., weight shifting, standing on one leg, etc.), activities of daily living training (i.e., reaching to grasp functionally relevant objects), and cognitive enhancement (i.e., memory training). By using the AR system, participants can observe the real performance of motions and interaction between the body and the virtual environment.
Study NCT05993091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: augmented reality (AR)
Description: The training program with different levels of difficulty provides goal-directed exercises designed to be adjustable in order to match the patient's ability to minimize compensatory movements. The goal-directed exercise includes balance training (i.e., weight shifting, standing on one leg, etc.), activities of daily living training (i.e., reaching to grasp functionally relevant objects), and cognitive enhancement (i.e., memory training). By using the AR system, participants can observe the real performance of motions and interaction between the body and the virtual environment.
Study NCT05993091 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: Participants will perform 90 minutes of therapist-mediated conventional therapy. The treatment protocols will be formulated by using occupational therapy techniques, such as neurodevelopmental techniques and functional task training. Specifically, the affected arm exercise or gross motor training, muscle strengthening of the affected arm, fine motor or dexterity training, and functional tasks of daily life or compensatory techniques will be used to alleviate functional deficits. In addition, the therapist will work with the participant to select functionally relevant tasks, such as picking up items from a box, lifting soft drink bottles, hanging clothes, and so on.
Study NCT04650126 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATM001
Description: monovalent anti-TNF-receptor 1 antibody format
Study NCT04650126 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ATM001 Placebo
Description: ATM001 Placebo
Study NCT05292976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Methacholine Chloride
Description: Serial Methacholine dilutions
Study NCT05292976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methacholine Chloride
Description: Serial Methacholine dilutions
Study NCT05292976 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Methacholine Chloride
Description: Serial Methacholine dilutions
Study NCT05292976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol Sulfate HFA 0.09 mg (Reference)
Description: One actuation each from the Reference inhalation aerosol and the placebo Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols.
Study NCT05292976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol Sulfate HFA 0.18 mg (Reference)
Description: One actuation each from two different Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols.
Study NCT04865055 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cyclic merocyanine
Description: long-UVA absorber
Study NCT04865055 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT05292976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate HFA 0.09 mg (Test)
Description: One actuation each from the Test inhalation aerosol and the placebo Test inhalation aerosol and one actuation each from two different placebo Reference inhalation aerosols.
Study NCT05292976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate HFA 0.18 mg (Test)
Description: One actuation each from two different Test inhalation aerosols and one actuation each from two different placebo Reference inhalation aerosols.
Study NCT05292976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One actuation each from two different placebo Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols.
Study NCT05571215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Five sessions of tDCS will be performed following completions of baseline data collection. This will include 3 sessions during week one and 2 sessions in week 2. A tDCS unit (neuroConn Ilmenau, Germany) will be applied to the left DLPFC with participants in the sitting position for a 20 minutes of tDCS. An anodal 2.0 mA current will be applied to each participant, including a 30-second ramp up at the beginning of stimulation and a 30 second ramp down period and the end of stimulation. The left DLPFC (F3 from EEG 10/20 system) will be located using the Beam F3 measurement system. These parameters are consistent with those used in current literature on tDCS for pain. tDCS procedures will be performed by the PI (CA).
Study NCT05571215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: Immediately following completion of each tDCS intervention, participants will be given a one-on-one PNE session provided also by the PT (CA), who is a licensed healthcare provider with expertise in delivery of the content. This educational session will last about 30 minutes. Initial sessions will involve discussion and questioning of participants about their own understanding of their pain and this information will be used to subsequently individualize the forthcoming educational sessions. The educational sessions will follow the content of Explain Pain, a patient booklet, and will include information on the neurophysiology of pain, pain as typical process, the transition from acute to chronic pain, neuroplasticity, central sensitization, factors that promote pain chronicity. Information will be presented verbally along with visuals on paper.
Study NCT05186259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Self-reported signs of central sensitization
Description: Self-reported signs of central sensitization by means of the Central Sensitization Inventory (questionnaire)
Study NCT05186259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Objective signs of central sensitization
Description: Objective signs of central sensitization by means of Quantitative Sensory Testing (mechanical and heat detection and pain thresholds, endogenous pain facilitation and inhibition)
Study NCT05186259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Audiological outcome measures (audiometry, tinnitus analysis, uncomfortable loudness) in tinnitus patients with and without pain
Description: * Audiometry Performance of pure tone audiometry according to the modified Hughson-Westlake method~* Tinnitus analysis Measurement of psychoacoustic features of tinnitus, including (1) tinnitus pitch, (2) loudness, (3) masking ability, and (4) residual inhibition.~* Uncomfortable Loudness measures Performance of Uncomfortable Loudness measurements to evaluate the presence of hyperacusis. .
Study NCT04160910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Hydroxytryptophan
Description: Double blinded placebo controlled. 28 day dosing period followed by 3 week washout period. Then crossover to other arm of study
Study NCT04160910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double blinded placebo controlled. 28 day dosing period followed by 3 week washout period. Then crossover to other arm of study
Study NCT05186259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive functioning
Description: Evaluation of cognitive functioning by means of:~* Auditory Stroop test~* Detecting letters task~* Letter-number sequencing task
Study NCT05186259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Listening effort
Description: Evaluation of listening effort by means of the modified version of the behavioral listening effort test based on a dual-task paradigm by Degeest, Keppler \& Corthals (2018) .
Study NCT05186259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Self-reported psychological factors
Description: Evaluation of psychological factors by means of:~* Depression, Anxiety and Stress Scale (DASS-21)~* Beck Depression Inventory (BDI)~* Big Five Inventory (BFI)~* Connor-Davidson Resilience Scale
Study NCT06409559 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: pelvic reconstruction
Description: interfragmentary screws placed through the plate or buttress plate applied under compression without interfragmentary lag or position screws
Study NCT05186259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Self-reported lifestyle factors
Description: Evaluation of lifestyle factors by means of:~Baecke Questionnaire Pittsburg Sleep Quality Index Insomnia Severity Index Stress subscale of the DASS 21
Study NCT05186259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Self-reported measure of pain processing
Description: Evaluation of self-reported pain processing by means of the Pain Catastrophizing Scale
Study NCT05186259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Self-reported quality of life
Description: Self-reported quality of life by means of the SF-36 questionnaire
Study NCT05186259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Self-reported tinnitus severity and impact on daily life
Description: Evaluation of self-reported tinnitus severity and impact on daily life by means of the Tinnitus Functional Index
Study NCT05186259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Self-reported hyperacusis
Description: Evaluation of self-reported characteristics of hyperacusis by means of the Hyperacusis Questionnaire
Study NCT05186259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Self-reported tinnitus characteristics
Description: Evaluation of self-reported tinnitus characteristics by means of the Tinnitus Sample Case History Questionnaire
Study NCT05186259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Self reported neck pain related disability
Description: Evaluation of self-reported neck pain related disability using the Neck Disability Index
Study NCT04703868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium 10mg
Description: Part A: 1 tablet administered before the breakfast during 7 days
Study NCT04703868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium 20mg
Description: Part B: 1 tablet administered before the breakfast during 7 days
Study NCT06488638 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nitrate-rich beetroot juice (70ml with approx. 400 mg nitrate) twice a day for 3 days
Description: commercially available beetroot juice dietary nitrate supplement
Study NCT06488638 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: nitrate-rich beetroot juice (70ml with approx. 400 mg nitrate) twice a day for 3 days
Description: commercially available beetroot juice dietary nitrate supplement
Study NCT05871918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCbHP VS ddEC-THP
Description: The efficacy was evaluated every two cycles, and the effective patients (CR, PR, SD) were treated with surgery after 6 cycles. If treatment does not work, change the treatment plan according to the clinician's decision.
Study NCT05871918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TCbHP VS ddEC-THP
Description: The efficacy was evaluated every two cycles, and the effective patients (CR, PR, SD) were treated with surgery after 6 cycles. If treatment does not work, change the treatment plan according to the clinician's decision.
Study NCT04964245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: accelometer
Description: the respiration parameters are measured using an accelometer.
Study NCT04964245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thermographic camera
Description: the respiration parameters are measured using an thermographic camera.
Study NCT04964245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Tomography
Description: the respiration parameters are measured using an electrical impedance tomograhy.
Study NCT04964245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mattress Sensor
Description: the respiration parameters are measured using an Mattress pressure
Study NCT05413863 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biocon's Human Insulin R U-500
Description: Biocon's Human Insulin R U-500 (Insulin Human Injection 500 units/mL), 3 mL cartridges (containing 1,500 units of insulin).
Study NCT05413863 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Humulin® R U-500 (US Reference Product)
Description: Humulin® R U-500 (US Reference Product), 3 mL single-patient-use KwikPen® (containing 1,500 units of insulin)
Study NCT05219578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTX-224
Description: RTX-224 monotherapy
Study NCT05466188 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CPC
Description: CPC
Study NCT05846438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Showering 48 hours after surgery
Description: The main intervention is allowing patients to shower 48 hours after surgery
Study NCT01304628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL-3994
Description: subcutaneous PL-3994, single dose, 4 escalating dose groups
Study NCT01304628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PL-3994
Description: subcutaneous PL-3994, single dose, 4 escalating dose groups